Compare SM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SM | BLTE |
|---|---|---|
| Founded | 1908 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.2B |
| IPO Year | 1996 | 2021 |
| Metric | SM | BLTE |
|---|---|---|
| Price | $31.46 | $154.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $34.36 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 4.0M | 90.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,154,000,000.00 | N/A |
| Revenue This Year | $129.01 | N/A |
| Revenue Next Year | $6.29 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.24 | N/A |
| 52 Week Low | $17.45 | $56.68 |
| 52 Week High | $33.25 | $200.00 |
| Indicator | SM | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 44.66 |
| Support Level | $25.18 | $148.06 |
| Resistance Level | $31.50 | $161.28 |
| Average True Range (ATR) | 1.18 | 5.75 |
| MACD | 0.04 | -0.40 |
| Stochastic Oscillator | 96.24 | 36.94 |
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.